PharmGen Science Inc banner

PharmGen Science Inc
KRX:004720

Watchlist Manager
PharmGen Science Inc Logo
PharmGen Science Inc
KRX:004720
Watchlist
Price: 3 815 KRW -0.52% Market Closed
Market Cap: ₩83.7B

Balance Sheet

Balance Sheet Decomposition
PharmGen Science Inc

Balance Sheet
PharmGen Science Inc

Rotate your device to view
Balance Sheet
Currency: KRW
Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
1 151
3 038
4 307
1 576
1 250
622
520
2 179
6 026
813
2 557
3 571
5 431
5 181
22 412
11 394
25 917
33 656
19 355
36 906
37 916
Cash Equivalents
1 151
3 038
4 307
1 576
1 250
622
520
2 179
6 026
813
2 557
3 571
5 431
5 181
22 412
11 394
25 917
33 656
19 355
36 906
37 916
Short-Term Investments
1 203
1 618
1 293
7 053
4 666
2 134
1 993
564
75
45
2 004
5 090
17 000
16 000
23 000
4 000
4 531
531
531
532
0
Total Receivables
19 256
23 546
28 031
31 333
38 607
31 172
24 541
22 212
20 336
20 261
17 794
19 370
16 696
20 232
20 134
19 772
24 020
20 166
28 638
36 414
39 662
Accounts Receivables
17 614
21 356
25 395
29 336
36 505
25 439
22 694
18 749
18 407
19 184
16 997
18 879
16 246
19 654
19 400
19 386
21 404
19 857
28 037
35 617
39 299
Other Receivables
1 642
2 190
2 636
1 997
2 102
5 733
1 847
3 463
1 929
1 077
797
491
450
578
734
386
2 616
309
600
797
362
Inventory
5 522
5 978
9 411
12 179
8 963
7 273
9 319
6 024
5 712
7 792
9 990
8 721
12 835
11 934
12 002
13 780
16 420
15 225
20 900
20 713
31 845
Other Current Assets
356
1 109
951
1 965
1 286
1 346
330
572
298
1 769
1 450
1 444
1 125
1 975
3 406
1 668
4 013
7 801
1 117
762
1 286
Total Current Assets
27 487
35 288
43 994
54 106
54 771
42 548
36 703
31 550
32 447
30 680
33 795
38 196
53 087
55 322
80 955
50 615
74 901
77 379
70 541
95 327
110 709
PP&E Net
3 078
3 501
4 429
7 437
7 542
3 864
7 692
7 322
7 125
6 415
5 939
5 950
8 348
8 839
8 618
15 595
17 214
34 902
42 444
41 273
38 863
PP&E Gross
3 078
3 501
4 429
7 437
7 542
3 864
7 692
7 322
7 125
6 415
5 939
5 950
8 348
8 839
8 618
15 595
17 214
34 902
42 444
41 273
38 863
Accumulated Depreciation
5 202
4 837
4 525
5 409
6 768
7 341
7 407
8 242
8 499
9 372
9 960
10 705
11 356
12 378
13 372
15 285
17 787
19 406
16 831
18 615
21 322
Intangible Assets
197
324
311
266
306
413
655
522
907
784
680
636
914
995
1 051
992
1 936
4 434
6 178
6 418
7 133
Goodwill
16 238
12 621
9 004
5 388
1 795
0
0
0
54
54
54
54
54
54
54
54
0
0
0
0
0
Note Receivable
0
0
0
0
0
0
0
0
884
870
872
617
0
728
725
784
532
857
477
442
409
Long-Term Investments
132
11 026
18 702
15 459
22 291
11 033
9 910
2 716
822
515
693
986
1 305
2 531
3 585
26 095
37 707
102 746
197 748
192 446
206 303
Other Long-Term Assets
2 354
3 707
2 359
1 831
1 948
1 066
773
714
375
11
11
11
593
11
3 206
5 901
3 253
5
4
11
33
Other Assets
16 238
12 621
9 004
5 388
1 795
0
0
0
54
54
54
54
54
54
54
54
0
0
0
0
0
Total Assets
49 485
N/A
66 467
+34%
78 800
+19%
84 487
+7%
88 653
+5%
58 924
-34%
55 734
-5%
42 824
-23%
42 614
0%
39 329
-8%
42 043
+7%
46 450
+10%
64 300
+38%
68 480
+7%
98 193
+43%
100 035
+2%
135 544
+35%
220 324
+63%
317 391
+44%
335 917
+6%
363 450
+8%
Liabilities
Accounts Payable
10 104
8 265
10 262
5 803
6 436
2 934
2 244
681
1 928
2 618
4 161
3 067
3 996
3 954
1 869
4 082
4 480
4 505
4 938
4 868
6 621
Accrued Liabilities
540
1 033
1 227
643
1 495
1 458
581
624
432
307
255
629
1 082
2 168
3 211
2 488
3 576
4 296
7 228
8 059
7 822
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
76
0
0
0
0
1 169
0
0
0
Current Portion of Long-Term Debt
8 404
13 689
15 980
28 658
31 674
18 229
19 682
12 670
6 779
4 650
9 064
4 143
10 000
0
19 125
18 352
20 388
46 262
39 001
37 431
38 640
Other Current Liabilities
3 201
3 493
3 410
4 519
12 115
7 286
6 617
7 702
4 555
4 478
4 200
4 966
6 699
3 964
8 763
5 418
9 243
14 890
17 017
12 814
12 339
Total Current Liabilities
22 249
26 480
30 879
39 624
51 720
29 908
29 123
21 677
13 695
12 053
17 681
12 805
21 853
10 086
32 968
30 340
37 688
71 122
68 185
63 172
65 422
Long-Term Debt
976
5 069
9 684
597
457
316
228
96
54
236
234
233
231
229
206
1 427
1 017
578
490
532
350
Deferred Income Tax
25
0
0
0
19
0
61
628
628
628
628
628
628
628
0
0
0
7 770
28 187
29 021
31 178
Minority Interest
0
0
0
0
0
0
76
99
46
34
71
55
37
76
104
142
44
8
9
10
11
Other Liabilities
1 326
1 848
1 615
1 785
1 646
1 649
1 497
1 731
2 333
2 578
3 384
4 126
5 180
6 484
8 173
12 021
13 269
13 923
13 414
14 981
17 072
Total Liabilities
24 575
N/A
33 397
+36%
42 177
+26%
42 006
0%
53 841
+28%
31 873
-41%
30 834
-3%
24 034
-22%
16 756
-30%
15 460
-8%
21 856
+41%
17 736
-19%
27 856
+57%
17 502
-37%
41 450
+137%
43 931
+6%
52 018
+18%
93 384
+80%
110 267
+18%
107 696
-2%
114 011
+6%
Equity
Common Stock
32 150
34 068
34 068
36 172
36 240
29 247
29 247
31 788
38 600
39 737
4 074
4 714
5 028
5 644
5 785
5 843
7 356
7 617
7 915
9 001
9 101
Retained Earnings
7 281
4 921
889
668
10 648
5 187
4 153
12 805
18 240
21 630
26 616
1 686
4 965
8 897
12 278
10 691
20 282
52 972
125 089
130 093
135 699
Additional Paid In Capital
0
3 270
1 482
7 590
8 980
3 824
637
620
6 324
6 588
43 584
23 170
27 306
37 285
39 529
41 243
59 229
65 502
69 897
81 599
82 597
Unrealized Security Profit/Loss
40
653
183
965
1 223
2
1
19
5
5
6
7
5
0
0
825
2 493
1 698
5 072
8 134
22 793
Treasury Stock
0
0
0
983
983
570
570
570
570
570
587
587
587
587
587
587
587
587
587
587
587
Other Equity
0
0
0
0
0
261
263
261
261
261
261
261
261
261
261
261
261
261
261
18
163
Total Equity
24 910
N/A
33 070
+33%
36 623
+11%
42 481
+16%
34 812
-18%
27 052
-22%
24 899
-8%
18 790
-25%
25 858
+38%
23 869
-8%
20 187
-15%
28 714
+42%
36 445
+27%
50 978
+40%
56 743
+11%
56 104
-1%
83 526
+49%
126 940
+52%
207 125
+63%
228 221
+10%
249 439
+9%
Total Liabilities & Equity
49 485
N/A
66 467
+34%
78 800
+19%
84 487
+7%
88 653
+5%
58 924
-34%
55 734
-5%
42 824
-23%
42 614
0%
39 329
-8%
42 043
+7%
46 450
+10%
64 300
+38%
68 480
+7%
98 193
+43%
100 035
+2%
135 544
+35%
220 324
+63%
317 391
+44%
335 917
+6%
363 450
+8%
Shares Outstanding
Common Shares Outstanding
4
4
4
5
5
6
6
7
8
8
8
9
10
11
12
12
15
15
16
18
18
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett